is rybelsus a glp 1 drug Novo's gains FDA expansion to reduce risk of MACE Exclusive ePass – Rybelsus Oral
Description
If successful, these options could reduce the aggregate number of devices required, which has led some industry stakeholders to consider them a sustainability lever
Wegovy and Zepbound, for example, can cost patients more than $1,000 a month
Diabetes & Metabolic Syndrome: Clinical Research & Reviews 19 , 103212 (2025).
Latif, W., Lambrinos, K
[DOI] [PMC free article] [PubMed] [Google Scholar] 82
As a word of caution, these favorable outcomes are preliminary and require confirmation
